Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....